AI model for diagnosing lymph node metastasis in nasopharyngeal carcinoma
Development and Validation of a Deep Learning Model for Diagnosing Lymph Node Metastasis in Nasopharyngeal Carcinoma Using Histologic Whole Slide Images and Time-dependent Magnetic Resonance Images
This study is testing a new AI tool that helps doctors diagnose if nasopharyngeal carcinoma has spread to lymph nodes by looking at MRI images before and after chemotherapy.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Sex | All |
| Sponsor | Sun Yat-sen University Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Guangzhou, Guangdong) |
| Trial ID | NCT06829147 on ClinicalTrials.gov |
What this trial studies
This study develops an artificial intelligence model to assist in diagnosing lymph node metastasis in patients with nasopharyngeal carcinoma. The model utilizes MRI images of the lymph nodes and surrounding areas, analyzing features before and after chemotherapy to track changes. It aims to automatically identify lymph nodes and predict the likelihood of metastasis based on both MRI and pathological data. The approach combines advanced imaging techniques with AI to enhance diagnostic accuracy.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with pathologically confirmed nasopharyngeal carcinoma who have undergone initial MRI and PET/CT scans.
Not a fit: Patients who have received cervical lymph node radiotherapy or have other concurrent malignant tumors may not benefit from this study.
Why it matters
Potential benefit: If successful, this AI model could significantly improve the accuracy of diagnosing lymph node metastasis in nasopharyngeal carcinoma, leading to better treatment decisions.
How similar studies have performed: Other studies utilizing AI for diagnostic purposes in oncology have shown promising results, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. The primary lesion was pathologically confirmed as nasopharyngeal carcinoma (WHO classification is I, II and III); 2. MRI scan was performed at the initial diagnosis (before anti-tumor treatment), and transverse and coronal MRI images before treatment were available, including T1-weighted, T2-weighted and T1-enhanced scanning sequences. 3. PET/CT scan was performed at the initial diagnosis (before anti-tumor treatment) 4. When MRI and PET/CT were inconsistent in judging the benign or malignant nature of lymph nodes, the patient agreed to undergo cervical lymph node puncture and pathological examination. Exclusion Criteria: 1. The patient has undergone cervical lymph node radiotherapy for any reason 2. Combined with other malignant tumors
Where this trial is running
Guangzhou, Guangdong
- Department of Radiation Oncology, Sun Yat-sen University Cancer Center — Guangzhou, Guangdong, China (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.